Veracyte stock
VCYTNASDAQVeracyte, Inc., HealthcareISIN US92337F1075
53Score 53 out of 100, Neutral
Price and trend
37 / 100
Price history
−42% in one yearThe chart shows daily closes over 13 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 42% below it.
Since June 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Sharply down: the price has fallen very quickly lately (RSI 24).
The price is 59% below its 52-week high. Largest decline in 13 years: 81% (February 2021 to October 2022).
Chart figures for advanced users
- SMA 50$42.57
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$42.46
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)24
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$24.00
- The lowest closing price of the last twelve months.
- Resistance$60.49
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Veracyte, Inc. belongs to the Medical (Diagnostics & Research) industry (United States) and, with a market value of $1.99B, is number 30 of 37 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $517.15M (up 16% year on year) and earnings of $66.35M (up 174.9%).
- For fiscal 2026, analysts expect on average revenue of $593.66M (up 14.8%) and adjusted earnings per share of $1.91 (up 6.8%).
Show more
- MEQIRI Score 53 out of 100 (Neutral): rank 356 of 702 in Healthcare, median 53.
- The P/E is 16.1 (Medical (Diagnostics & Research) median 33.7, own median of recent years 86.9).
- Our model puts fair value at $42.82, with the price 42% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Growing faster than its industryRevenue up 34.5% a year since 2020, Medical (Diagnostics & Research) median 6.6%.Growth 70
- Modestly valuedP/E 16.1, Medical (Diagnostics & Research) median 33.7, own median 86.9.Valuation 68
- More cash than debtCash $370.53M, financial debt $40.74M.Stability 77
Weaknesses
- DilutionShare count up 48% since 2020.Capital allocation 35
- Volatile share priceVolatility 81% a year over the last 12 months.
- Share price fell sharplyDown 42% over the last 12 months.Momentum 12
Its standout strengths are stability and profitability, while capital allocation and momentum hold the score back.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk high
How well MEQIRI warnsOne of the 30% with the highest crash risk among smaller stocks.
From 2016 to 2025, 36 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What drives the risk
- high price swings
- price far below its 52-week high
- weak fundamentals
What lowers it
- price not overheated over the past year
Valuation
Valuation signal
Significantly undervaluedIn our model the price counts as cheap below $28.55 and expensive above $85.64 (uncertainty very high, based on the price swings of the past year).
The two parts of the fair value come to $34.05 (cash-flow model) and $51.59 (industry comparison), and the gap between them shows how uncertain the estimate is. The price is below both.
Calculated with a cost of equity of 9.1%. At 10.1% the fair value would be $40.26, at 8.1% it would be $46.55.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (33.7).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 17.5% on the twelve months before. Revenue has grown strongly since 2011, at around 46% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 70%, operating 14%, net 13%. Last 12 months: net 22%.
Debt & balance sheet
latest quarterThe balance sheet is solid, with low debt and comfortable interest coverage.
Earnings
- Next earnings
- 24 Feb 2027in 103 days
- Last reported
- 4 Nov 2026EPS reported $0.51 (expected $0.41)above expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- $1.91−0.1%
- Revenue
- $593.66M0.0%
- Earnings per share
- $1.90−2.3%
- Revenue
- $657.06M−0.2%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook raised
Share price after the results: +23.1%2026 revenue guidance raised to $582 million to $592 million (from $570 million to $582 million), adjusted EBITDA margin guidance raised to above 26%.
“We are raising full year total revenue guidance to $582 million to $592 million, representing 13% to 14% year-over-year growth compared to our prior range of $570 million to $582 million.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 5 May 2026 (fiscal Q1 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. 10 insiders sold, $12.54M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Holstein JensSale
27 Oct 2026, Board
- Shares
- 7,500
- Price
- $50.00
- Value
- $375,000
- Eastham KarinSale
27 Oct 2026, Board
- Shares
- 14,850
- Price
- $50.00
- Value
- $742,573
- Bhanji MunaSale
19 Oct 2026, Board
- Shares
- 1,864
- Price
- $43.70
- Value
- $81,457
Show 14 more
- Holstein JensSale
24 Sept 2026, Board
- Shares
- 7,500
- Price
- $47.00
- Value
- $352,500
- Leite JohnSale
21 Sept 2026, Global Chief Commercial Officer
- Shares
- 4,015
- Price
- $40.00
- Value
- $160,600
- Holstein JensSale
14 Sept 2026, Board
- Shares
- 5,000
- Price
- $40.95
- Value
- $204,747
- Febbo Phillip G.Sale
4 Sept 2026, Chief Scientific & Med Officer
- Shares
- 13,110
- Price
- $43.05
- Value
- $564,410
- Chambers RebeccaSale
4 Sept 2026, Chief Financial Officer
- Shares
- 3,652
- Price
- $43.10
- Value
- $157,394
- McGuire AnnieSale
4 Sept 2026, EVP, General Counsel
- Shares
- 3,254
- Price
- $43.09
- Value
- $140,212
- Bhanji MunaSale
1 Sept 2026, Board
- Shares
- 1,864
- Price
- $42.97
- Value
- $80,096
- Eastham KarinSale
18 Jun 2026, Board
- Shares
- 3,729
- Price
- $52.89
- Value
- $197,234
- McGuire AnnieSale
4 Jun 2026, EVP, General Counsel
- Shares
- 3,176
- Price
- $49.76
- Value
- $158,036
- Chambers RebeccaSale
4 Jun 2026, Chief Financial Officer
- Shares
- 3,561
- Price
- $49.73
- Value
- $177,083
- Stapley MarcSale
4 Jun 2026, Chief Executive Officer
- Shares
- 138,051
- Price
- $50.12
- Value
- $6.92M
- Leite JohnSale
4 Jun 2026, Global Chief Commercial Officer
- Shares
- 13,975
- Price
- $50.07
- Value
- $699,732
- Wygant JonathanSale
22 May 2026, VP, Chief Accounting Officer
- Shares
- 24,000
- Price
- $45.40
- Value
- $1.09M
- Epstein Robert SSale
20 May 2026, Board
- Shares
- 10,000
- Price
- $44.01
- Value
- $440,129
Partial trades from one filing are shown in one row, with the average price.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Veracyte
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 53
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Diagnostics & Research)
The next larger and next smaller companies by market value
- Sotera HealthSHC $4.65B54
- CareDxCDNA $4.19B59
- Vimian GroupVIMIAN.ST $2.23B58
- NeoGenomicsNEO $2.15B39
- PersonalisPSNL $1.72B41
- GeneDx HoldingsWGS $1.55B37
- OPKO HealthOPK $1.24B37
- Castle BiosciencesCSTL $1.06B45
ETFs that hold Veracyte
Held by 19 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| Global X Telemedicine & Digital Health UCITS ETFDDOC | 2.33% | 0.68% | €5.31M |
| Global X Genomics & Biotechnology UCITS ETFGN0M | 1.50% | 0.50% | €127.64M |
| L&G Healthcare Technology & Innovation UCITS ETFXMLH | 0.92% | 0.49% | €318.64M |
Show 5 more
| L&G Artificial Intelligence UCITS ETFXMLD | 0.92% | 0.49% | €1.96B |
| L&G Russell 2000 US Small Cap Quality UCITS ETFETLZ | 0.26% | 0.30% | €185.82M |
| iShares Healthcare Innovation UCITS ETF2B78 | 0.19% | 0.40% | €1.5B |
| iShares Nasdaq US Biotechnology UCITS ETF2B70 | 0.12% | 0.35% | €1.25B |
| iShares S&P SmallCap 600 UCITS ETFIUS3 | 0.11% | 0.30% | €2.31B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 27 Feb 2026)
- Valuation signal Undervalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.